PATENT CLAIM ANALYSIS

Application Number: 15987011
Application Type: Utility
Filing Date: 2018-05
Publication Date: 2018-09
Patent Classification: ["424", "009100"]

Abstract:
S1P receptor modulators are administered following a dosage regimen providing a positive benefit-risk profile.

Claim (Index 25):
A method for treating relapsing remitting multiple sclerosis in a patient in need thereof, wherein the patient has diabetes, to limit risk of adverse effects of fingolimod, comprising\n (A) performing an ophthalmologic examination before starting administration of fingolimod or of a pharmaceutically acceptable salt thereof; (B) administering orally to the patient a daily dosage of 0.5 mg of fingolimod or a pharmaceutically acceptable salt thereof; (C) performing a further ophthalmologic examination at about 3 to about 4 months after starting administration; (D) if the results of the further ophthalmologic examination performed in step (C) indicate macular edema, then interrupting the administration, thereby limiting the risk of adverse effects.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 93.0
- Lexical Diversity: 1.07143
- Patent Class: 424.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15986992', '15534929', '12655049', '13640857', '14973105']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.6713140994304468
- 35 USC 102 Novelty (BERT): 0.5600607234953133
- Combined Prediction Score: 0.6601887618369335
- Mean Citation Score: 276.313602
- Max Citation Score: 427.91425
- Similarity Product: 335.8148321903646

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test